PL2205244T3 - Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych - Google Patents

Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych

Info

Publication number
PL2205244T3
PL2205244T3 PL08847113T PL08847113T PL2205244T3 PL 2205244 T3 PL2205244 T3 PL 2205244T3 PL 08847113 T PL08847113 T PL 08847113T PL 08847113 T PL08847113 T PL 08847113T PL 2205244 T3 PL2205244 T3 PL 2205244T3
Authority
PL
Poland
Prior art keywords
benzothiazol
isoxazol
morpholin
imidazo
ethoxy
Prior art date
Application number
PL08847113T
Other languages
English (en)
Inventor
Joyce K James
Shawn R Eichelberger
Traci L Savall
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of PL2205244T3 publication Critical patent/PL2205244T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
PL08847113T 2007-11-08 2008-11-07 Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych PL2205244T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US258307P 2007-11-08 2007-11-08
US580307P 2007-12-07 2007-12-07
US9867608P 2008-09-19 2008-09-19
US11206008P 2008-11-06 2008-11-06
EP08847113.1A EP2205244B1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]-phenyl}urea to treat proliferative disease
PCT/US2008/012539 WO2009061446A1 (en) 2007-11-08 2008-11-07 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Publications (1)

Publication Number Publication Date
PL2205244T3 true PL2205244T3 (pl) 2014-01-31

Family

ID=40262072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08847113T PL2205244T3 (pl) 2007-11-08 2008-11-07 Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych

Country Status (18)

Country Link
US (1) US7968543B2 (pl)
EP (2) EP2205244B1 (pl)
JP (2) JP5645667B2 (pl)
KR (2) KR20150105494A (pl)
CN (1) CN101835472A (pl)
AR (1) AR069244A1 (pl)
AU (1) AU2008325141B2 (pl)
CA (1) CA2696807C (pl)
CY (1) CY1114853T1 (pl)
DK (1) DK2205244T3 (pl)
ES (1) ES2436266T3 (pl)
HR (1) HRP20131083T1 (pl)
MX (1) MX2010002396A (pl)
PL (1) PL2205244T3 (pl)
PT (1) PT2205244E (pl)
SI (1) SI2205244T1 (pl)
TW (1) TW200924756A (pl)
WO (1) WO2009061446A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101549364B1 (ko) 2006-03-17 2015-09-01 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
US8883783B2 (en) * 2007-09-19 2014-11-11 Ambit Biosciences Corporation Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
JP5762426B2 (ja) 2009-11-05 2015-08-12 アムビト ビオスシエンセス コルポラチオン イミダゾ［２，１−ｂ］［１，３］ベンゾチアゾール誘導体の調製方法
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513252B (zh) * 2013-09-26 2017-11-10 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
EP3174859B1 (en) 2014-07-31 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists
MX383857B (es) 2014-12-22 2025-03-14 Genzyme Corp Métodos de cultivo de una célula de mamífero.
KR102595395B1 (ko) 2015-02-20 2023-10-27 다이이찌 산쿄 가부시키가이샤 암의 병용 치료법
JP6793401B2 (ja) * 2015-03-11 2020-12-02 国立研究開発法人理化学研究所 難治性白血病治療薬
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
CA3062981A1 (en) 2017-05-17 2018-11-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Flt3 inhibitors for improving pain treatments by opioids
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN113966331B (zh) * 2020-03-11 2024-04-12 暨南大学 含脲结构的三芳环化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233903A (en) * 1880-11-02 Velocipede
US233906A (en) * 1880-11-02 Combined stirrer and thermometer
US994635A (en) * 1911-01-10 1911-06-06 Harry C Buhoup Car-truck.
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
KR101549364B1 (ko) 2006-03-17 2015-09-01 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
US8883783B2 (en) * 2007-09-19 2014-11-11 Ambit Biosciences Corporation Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Also Published As

Publication number Publication date
ES2436266T3 (es) 2013-12-30
CA2696807A1 (en) 2009-05-14
EP2596795A1 (en) 2013-05-29
TW200924756A (en) 2009-06-16
US20090123418A1 (en) 2009-05-14
CA2696807C (en) 2017-11-28
KR20100075853A (ko) 2010-07-05
AU2008325141B2 (en) 2014-03-20
PT2205244E (pt) 2013-11-26
WO2009061446A1 (en) 2009-05-14
JP5645667B2 (ja) 2014-12-24
AU2008325141A1 (en) 2009-05-14
JP2014221765A (ja) 2014-11-27
HRP20131083T1 (hr) 2013-12-20
EP2205244A1 (en) 2010-07-14
CY1114853T1 (el) 2016-12-14
JP2011503063A (ja) 2011-01-27
CN101835472A (zh) 2010-09-15
AR069244A1 (es) 2010-01-06
KR20150105494A (ko) 2015-09-16
EP2205244B1 (en) 2013-08-21
KR101578481B1 (ko) 2015-12-17
US7968543B2 (en) 2011-06-28
MX2010002396A (es) 2010-04-01
DK2205244T3 (da) 2013-11-25
SI2205244T1 (sl) 2013-12-31

Similar Documents

Publication Publication Date Title
PL2205244T3 (pl) Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
BRPI0816904B8 (pt) Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida
NI201200072A (es) Métodos y composiciones para tratar cáncer
ZA200707531B (en) N-(N-Sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
PL2024368T3 (pl) Pochodne 6,7,8,9-tetrahydro-5H-pirymido[4,5-d]azepin-4-ylo]-aminy jako modulatory TRPV1 do leczenia bólu
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
BRPI0821688A2 (pt) mistura para o tratamento de fertilizantes contendo uréia
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CL2007003742A1 (es) Compuestos derivados heterociclicos, inhibidores de protein quinasas activadas por mitogenos; proceso de preparacion; composicion farmaceutica; articulo de manufactura; y uso para el tratamiento de enfermedades tales como trastornos hiperproliferativ
PL2117525T3 (pl) Zastosowanie związków 1-fenylo-3-dimetyloaminopropanu do terapii bólu neuropatycznego
EP2134736A4 (en) FIVE- AND SIX-PIECE CONFORMATIVELY FIXED 2 ', 4'-CARBOCYCLIC RIBOTHYMIDINE FOR THE TREATMENT OF INFECTIONS AND CANCER
NZ604379A (en) Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA201000866A1 (ru) Производные амидов 6,7-дигидро-5н-имидазо[1,2-а]имидазол-3-карбоновой кислоты
NO20084270L (no) Anvendelse av imidazo[2,1-b] -1,3,4-tiadiazol-2-sulfonamidforbindelser for behandling av nevropatisk smerte
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
CU20120081A7 (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
IL213703A (en) Compounds for the treatment of pain and other diseases
PL2320878T3 (pl) Monoterpeny do leczenia chorób dróg oddechowych, w szczególności chorób oskrzelowo-płucnych
EP2154138A4 (en) NOVEL COMPOUNDS FOR THE TREATMENT OF PSYCHOTIC DISORDERS, METHODS OF PREPARATION, AND USES THEREOF
MX2009011819A (es) Formulaciones de aminoacido n-halogenado.